Gregory M. Weinhoff, Chief Business Officer at Centessa Pharmaceuticals plc (NASDAQ:CNTA), a company that has seen its stock surge over 117% in the past year according to InvestingPro data, recently reported transactions involving the company’s ordinary shares. On December 26, Weinhoff sold 10,000 shares at a weighted average price of $17.04, totaling $170,399. This sale was conducted under a pre-arranged Rule 10b5-1 trading plan, which Weinhoff adopted on May 22, 2024. With a current market capitalization of $2.23 billion and analysts setting price targets between $24 and $35, InvestingPro subscribers can access detailed insights about the company’s valuation and growth prospects.
In addition to the sale, Weinhoff also acquired 10,000 ordinary shares through the exercise of share options at a price of $3.85 per share, amounting to $38,500. Following these transactions, Weinhoff holds 183,266 shares directly.
The ordinary shares of Centessa Pharmaceuticals may be represented by American Depositary Shares, each corresponding to one ordinary share.
In other recent news, Centessa Pharmaceuticals has been the focus of several significant updates. Leerink Partners increased the stock’s price target to $24, reflecting a more optimistic view on Centessa’s product pipeline, particularly the ORX750 program. Guggenheim also raised its price target for Centessa to $28, maintaining a buy rating based on strategic developments, especially updates for ORX750. BMO Capital Markets maintained its Outperform rating and a $35.00 price target for Centessa, based on new data for ORX142, supporting the company’s leading position in the orexin agonist market. Oppenheimer also maintained its positive stance on Centessa with an Outperform rating and a steady price target of $24.00, buoyed by promising preclinical data for ORX142.
Morgan Stanley (NYSE:MS) upgraded Centessa to Overweight, raising the price target to $26, following the promising interim Phase 1 results of the company’s ORX750 study. Centessa is also actively working to strengthen its competitive edge by revealing a third orexin agonist aimed at addressing unmet needs in neuro-psychiatric disorders. Leerink Partners has increased its projections for Centessa’s total company sales in 2032 by 4%, from $1.2 billion to $1.3 billion, and earnings per share (EPS) by 18%, from $4.42 to $5.21.
These recent developments highlight Centessa’s ongoing efforts in the pharmaceutical industry, with a focus on its ORX750 and ORX142 programs. These programs are expected to yield new data in the coming years, providing further insights into their potential impacts on narcolepsy and idiopathic hypersomnia treatments.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.